Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
  • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
  • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Definitions

• the present invention relates to drug and nutrient delivery systems, and in particular to pharmaceutical compositions and methods for the improved solubilization of triglycerides and improved delivery of therapeutic agents.
• a wide variety of therapeutic agents such as drugs, nutritional agents, and cosmeceuticals, are conventionally formulated in oil/water emulsion systems. These conventional emulsions take advantage of the increased solubility of many therapeutic agents in oils (triglycerides).
• oils triglycerides
• one conventional approach is to solubilize a therapeutic agent in a bioacceptable triglyceride solvent, such as a digestible vegetable oil, and disperse this oil phase in an aqueous solution.
• the dispersion may be stabilized by emulsifying agents and provided in emulsion form.
• the therapeutic agent can be provided in a water-free formulation, with an aqueous dispersion being formed in vivo in the gastrointestinal environment.
• a triglyceride-containing formulation suitable for delivering therapeutic agents through an aqueous environment is an oil-in-water emulsion.
• Such emulsions contain the hydrophobic therapeutic agent solubilized in an oil phase which is dispersed in an aqueous environment with the aid of a surfactant.
• the surfactant may be present in the oil-based formulation itself, or may be a compound provided in the gastrointestinal system, such as bile salts, which are known to be in vivo emulsifying agents.
• colloidal oil particles sizes are relatively large, ranging from several hundred nanometers to several microns in diameter, in a broad particle size distribution. Since the particle sizes are on the order of or greater than the wavelength range of visible light, such emulsions, when prepared in an emulsion dosage form, are visibly “cloudy” or “milky” to the naked eye.
• Emulsions are thermodynamically unstable, and colloidal emulsion particles will spontaneously agglomerate, eventually leading to complete phase separation.
• the tendency to agglomerate and phase separate presents problems of storage and handling, and increases the likelihood that pharmaceutical emulsions initially properly prepared will be in a less optimal, less effective, and poorly-characterized state upon ultimate administration to a patient.
• Uncharacterized degradation is particularly disadvantageous, since increased particle size slows the rate of transport of the colloidal particle and digestion of the oil component, and hence the rate and extent of absorption of the therapeutic agent.
• a further disadvantage of conventional triglyceride-containing compositions is the dependence of therapeutic agent absorption on the rate and extent of lipolysis.
• colloidal emulsion particles can transport therapeutic agents through the aqueous environment of the gastrointestinal tract, ultimately the triglyceride must be digested and the therapeutic agent must be released in order to be absorbed through the intestinal mucosa.
• the triglyceride carrier is emulsified by bile salts and hydrolyzed, primarily by pancreatic lipase. The rate and extent of lipolysis, however, are dependent upon several factors that are difficult to adequately control.
• the amount and rate of bile salt secretion affect the lipolysis of the triglycerides, and the bile salt secretion can vary with stomach contents, with metabolic abnormalities, and with functional changes of the liver, bile ducts, gall bladder and intestine.
• Lipase availability in patients with decreased pancreatic secretory function, such as cystic fibrosis or chronic pancreatitis may be undesirably low, resulting in a slow and incomplete triglyceride lipolysis.
• the activity of lipase is pH dependent, with deactivation occurring at about pH 3, so that the lipolysis rate will vary with stomach contents, and may be insufficient in patients with gastric acid hyper-secretion.
• surfactants commonly used in the preparation of pharmaceutical emulsions such as polyethoxylated castor oils
• certain surfactant combinations when used in combination with digestible oils in emulsion preparations, can substantially decrease the lipolysis-inhibiting effect of some common pharmaceutical surfactants (see, U.S. Patent No. 5,645,856), such formulations are still subject to the other disadvantages of pharmaceutical emulsions and triglyceride-based formulations.
• microemulsions Like an emulsion, a microemulsion is a liquid dispersion of oil in water, stabilized by surfactants. Conventional microemulsions, however, present several safety and efficiency problems. The amount of triglyceride that can be solubilized in a conventional microemulsion is generally quite small, resulting in a poor loading capacity. In order to solubilize significant amounts of triglycerides, large amounts of hydrophilic surfactant and/or solvents must be used. These high concentrations of hydrophilic surfactant and solvents raise questions of safety, since the levels of hydrophilic surfactant and solvent needed can approach or exceed bioacceptable levels.
• the present invention provides pharmaceutical compositions for improved solubilization of triglycerides, and improved delivery of therapeutic agents. It has been surprisingly found that pharmaceutical compositions containing significant amounts of triglycerides can be formed without the disadvantages of conventional triglyceride- containing compositions by using a combination of surfactants and triglycerides in amounts such that when the pharmaceutical composition is mixed with an aqueous solution, a clear aqueous dispersion is formed. Such compositions can be co-administered with a therapeutic agent to increase the rate and/or extend of bioabsorption of the therapeutic agent, or can be provided with a therapeutic agent in the preconcentrate composition or in the diluent solution.
• the present invention relates to pharmaceutical compositions having a triglyceride and a carrier, the carrier including at least two surfactants, at least one of which is hydrophilic.
• the triglyceride and surfactants are present in amounts such that upon mixing with an aqueous solution, either in vitro or in vivo, the composition forms a clear aqueous dispersion.
• the composition is capable of containing more triglyceride than can be solubilized in a clear aqueous dispersion having only one surfactant, the surfactant being hydrophilic.
• the present invention relates to pharmaceutical compositions having a triglyceride and a carrier, the carrier including at least one hydrophilic surfactant and at least one hydrophobic surfactant.
• the triglyceride and surfactants are present in amounts such that upon mixing with an aqueous solution, either in vitro or in vivo, the composition forms a clear aqueous dispersion.
• the composition is capable of containing more triglyceride than can be solubilized in a clear aqueous dispersion having a hydrophilic surfactant but not having a hydrophobic surfactant..
• the triglyceride itself can have therapeutic value as, for example, a nutritional oil, or absorption-promoting value as, for example, a long-chain triglyceride ("LCT", having fatty acid chains longer than C 10 and preferably Cj 2 - C 22 ) or a medium-chain triglyceride ("MCT", having C 6 -C 10 fatty acid chains).
• LCT long-chain triglyceride
• MCT medium-chain triglyceride
• the present invention provides pharmaceutical compositions including a triglyceride having nutritional and/or absorption-promoting value, and a carrier.
• the carrier includes at least two surfactants, at least one of which is hydrophilic.
• the carrier can include at least one hydrophilic surfactant and at least one hydrophobic surfactant.
• the triglyceride and surfactants are present in amounts such that upon dilution with an aqueous solution, either in vitro or in vivo, the composition forms a clear
• the present invention relates to methods of increasing the amount of triglyceride that can be solubilized in an aqueous system, by providing a composition including a triglyceride and a carrier, the carrier including at least two surfactants, at least one of which is hydrophilic, and dispersing the composition in an aqueous solution so that a clear aqueous dispersion is formed.
• the triglyceride is capable of being solubilized in an amount greater than the amount of the triglyceride that remains solubilized in an aqueous dispersion of the triglyceride and a carrier having only one surfactant and having the same total surfactant concentration.
• the carrier can include at least one hydrophilic surfactant and at least one hydrophobic surfactant.
• the present invention relates to triglyceride-containing pharmaceutical compositions as described in the preceding embodiments, which further include a therapeutic agent.
• the therapeutic agent is a hydrophobic drug or a hydrophilic drug.
• the therapeutic agent is a nutritional agent.
• the therapeutic agent is a cosmeceutical agent.
• the present invention relates to methods of increasing the solubilization of a therapeutic agent in a composition, by providing the therapeutic agent in a composition ofthe present invention.
• the present invention relates to a pharmaceutical composition which includes a therapeutic agent, a triglyceride and a carrier.
• the carrier includes at least two surfactants, at least one of which is hydrophilic.
• the carrier includes at least one hydrophilic surfactant and at least one hydrophobic surfactant.
• the triglyceride, and surfactants are present in amounts such that upon dilution with an aqueous solution, either in vitro or in vivo, the composition forms a clear aqueous dispersion.
• the therapeutic agent is present in two amounts, a first amount of the therapeutic agent solubilized in the clear aqueous dispersion, and a second amount of the therapeutic agent that remains non-solubilized but dispersed.
• the present invention relates to methods of increasing the rate and/or extent of absorption of therapeutic agents by administering to a patient a pharmaceutical composition of the present invention.
• the therapeutic agent can be present in the pharmaceutical composition pre-concentrate, in the diluent, or in a second pharmaceutical composition, such as a conventional commercial formulation, which is co-administered with a pharmaceutical composition ofthe present invention.
• the present invention overcomes the problems described above characteristic of conventional triglyceride-containing formulations by providing unique pharmaceutical compositions which form clear aqueous dispersions upon mixing with an aqueous solution.
• compositions including triglycerides and a combination of surfactants can solubilize therapeutically effective amounts of therapeutic agents in homogeneous, single-phase systems which are thermodynamically stable and optically clear.
• the optical clarity is indicative of a very small particle size within the aqueous dispersions, and this small particle size substantially reduces lipolysis dependence of the rate of bioabsorption, and other disadvantages of conventional triglyceride-containing formulations.
• compositions of the present invention are surprisingly able to solubilize greater amounts of triglycerides than conventional formulations, even when the total surfactant concentration is the same as in a conventional formulation.
• the present invention provides a pharmaceutical composition including a triglyceride and a carrier.
• the carrier includes at least two surfactants, at least one of which is a hydrophilic surfactant.
• the carrier includes at least one hydrophilic surfactant and at least one hydrophobic surfactant.
• the triglyceride and surfactants are present in amounts such that upon dilution with an aqueous solution, either in vitro or in vivo, the composition forms a clear aqueous dispersion. It is a particular and surprising feature of the present invention that the composition is homogeneous and optically clear, despite the presence of substantial amounts of triglycerides, thereby providing surprising and important advantages over conventional triglyceride-containing formulations.
• compositions of the present invention include one or more pharmaceutically acceptable triglycerides.
• triglycerides suitable for use in the present invention are shown in Table 1. In general, these triglycerides are readily available from commercial sources. For several triglycerides, representative commercial products and/or commercial suppliers are listed. Table 1 : Triglycerides
• Glyceryl triarchidate (Sigma)
• Glyceryl trimyristoleate (Sigma)
• Glyceryl tricaprylate/caprate Captex 300 (Abitec); Captex 355 (Abitec); Miglyol 810 (H ⁇ ls); Miglyol 812 (H ⁇ ls)
• Glyceryl tricaprylate/caprate/laurate Captex 350 (Abitec)
• Glyceryl tricaprylate/caprate/linoleate Captex 810 (Abitec); Miglyol 818 (H ⁇ ls)
• Glyceryl tricaprylate/caprate/stearate Softisan 378 H ⁇ ls; (Larodan) Glyceryl tricaprylate/laurate/stearate (Larodan) Glyceryl l,2-caprylate-3-linoleate (Larodan) Glyceryl l,2-caprate-3-stearate (Larodan) Glyceryl l,2-laurate-3-myristate (Larodan) Glyceryl l,2-myristate-3-laurate (Larodan) Glyceryl l,3-palmitate-2-butyrate (Larodan) Glyceryl l,3-stearate-2-caprate (Larodan) Glyceryl l,2-linoleate-3-caprylate (Larodan) "
• Fractionated triglycerides modified triglycerides, synthetic triglycerides, and mixtures of triglycerides are also within the scope ofthe invention.
• Preferred triglycerides include vegetable oils, fish oils, animal fats, hydrogenated vegetable oils, partially hydrogenated vegetable oils, medium and long-chain triglycerides, and structured triglycerides. It should be appreciated that several commercial surfactant compositions contain small to moderate amounts of triglycerides, typically as a result of incomplete reaction of a triglyceride starting material in, for example, a transesterification reaction. Such commercial surfactant compositions, while nominally referred to as "surfactants”, may be suitable to provide all or part of the triglyceride component for the compositions of the present invention. Examples of commercial surfactant compositions containing triglycerides include some members of the surfactant families Gelucires (Gattefosse), Maisines (Gattefosse), and Imwitors (H ⁇ ls). Specific examples of these compositions are:
• Gelucire 50/13 saturated polyglycolized glycerides
• Gelucire 53/10 saturated polyglycolized glycerides
• Gelucire 33/01 (semi-synthetic triglycerides of C 8 -C 18 saturated fatty acids)
• Gelucire 39/01 (semi-synthetic glycerides) other Gelucires, such as 37/06, 43/01, 35/10, 37/02, 46/07, 48/09, 50/02, 62/05, etc.
• Maisine 35-1 (linoleic glycerides)
• Imwitor 742 (caprylic/capric glycerides)
• compositions having significant triglyceride content are known to those skilled in the art. It should be appreciated that such compositions, which contain triglycerides as well as surfactants, may be suitable to provide all or part of the triglyceride component of the compositions of the present invention, as well as all or part of the surfactant component, as described below. Of course, none of the commonly known triglyceride-containing commercial surfactants alone provides the unique pharmaceutical compositions and characteristics as recited in the appended claims.
• preferred triglycerides include: almond oil; babassu oil; borage oil; blackcurrant seed oil; canola oil; castor oil; coconut oil; com oil; cottonseed oil; evening primrose oil; grapeseed oil; groundnut oil; mustard seed oil; olive oil; palm oil; palm kernel oil; peanut oil; rapeseed oil; safflower oil; sesame oil; shark liver oil; soybean oil; sunflower oil; hydrogenated castor oil; hydrogenated coconut oil; hydrogenated palm oil; hydrogenated soybean oil; hydrogenated vegetable oil; hydrogenated cottonseed and castor oil; partially hydrogenated soybean oil; partially soy and cottonseed oil; glyceryl tricaproate; glyceryl tricaprylate; glyceryl tricaprate; glyceryl triundecanoate; glyceryl trilaurate; glyceryl trioleate; glyceryl trilinoleate; glyceryl trilinooleate; glyceryl trilin
• triglycerides are saturated polyglycolized glycerides (Gelucire 44/14, Gelucire 50/13 and Gelucire 53/10), linoleic glycerides (Maisine 35-1), and caprylic/capric glycerides (Imwitor 742).
• more preferred triglycerides include: coconut oil; com oil; olive oil; palm oil; peanut oil; safflower oil; sesame oil; soybean oil; hydrogenated castor oil; hydrogenated coconut oil; partially hydrogenated soybean oil; glyceryl tricaprate; glyceryl trilaurate; glyceryl trioleate; glyceryl trilinoleate; glyceryl tricaprylate/caprate; glyceryl tricaprylate/caprate/laurate; glyceryl tricaprylate/caprate/linoleate; glyceryl tricaprylate/caprate/stearate; saturated polyglycolized glycerides (Gelucire 44/14, Gelucire 50/13 and Gelucire 53/10); linoleic glycerides (Maisine 35-1); and caprylic/capric glycerides (Imwitor 742).
• the carrier includes a combination of surfactants, at least one of which is a hydrophilic surfactant, with the remaining surfactant or surfactants being hydrophilic or hydrophobic.
• hydrophilic and “hydrophobic” are relative terms.
• a compound must necessarily include polar or charged hydrophilic moieties as well as non-polar hydrophobic (lipophilic) moieties; i.e., a surfactant compound must be amphiphilic.
• An empirical parameter commonly used to characterize the relative hydrophilicity and hydrophobicity of non-ionic amphiphilic compounds is the hydrophilic-lipophilic balance (the "HLB” value).
• HLB hydrophilic-lipophilic balance
• hydrophilic surfactants are generally considered to be those compounds having an HLB value greater than about 10, as well as anionic, cationic, or zwitterionic compounds for which the HLB scale is not generally applicable.
• hydrophobic surfactants are compounds having an HLB value less than about 10.
• HLB value of a surfactant is merely a rough guide generally used to enable formulation of industrial, pharmaceutical and cosmetic emulsions.
• HLB values can differ by as much as about 8 HLB units, depending upon the empirical method chosen to determine the HLB value (Schott, J. Pharm. Sciences, 79(1), 87-88 (1990)).
• polypropylene oxide containing block copolymers polypropylene oxide containing block copolymers, available commercially as PLURONIC® surfactants, BASF Corp.
• the HLB values may not accurately reflect the true physical chemical nature of the compounds.
• the carrier of the present invention includes at least one hydrophilic surfactant.
• the hydrophilic surfactant can be any surfactant suitable for use in pharmaceutical compositions. Suitable hydrophilic surfactants can be anionic, cationic, zwitterionic or non-ionic, although non-ionic hydrophilic surfactants are presently preferred.
• the carrier includes a mixture of two or more hydrophilic surfactants, more preferably two or more non-ionic hydrophilic surfactants. Also preferred are mixtures of at least one hydrophilic surfactant, preferably non-ionic, and at least one hydrophobic surfactant.
• surfactants should be made keeping in mind the particular triglycerides and optional therapeutic agents to be used in the composition, and the range of polarity appropriate for the chosen therapeutic agent. With these general principles in mind, a very broad range of surfactants is suitable for use in the present invention. Such surfactants can be grouped into the following general chemical classes detailed in the Tables herein.
• the HLB values given in the Tables below generally represent the HLB value as reported by the manufacturer of the corresponding commercial product. In cases where more than one commercial product is listed, the HLB value in the Tables is the value as reported for one of the commercial products, a rough average of the reported values, or a value that, in the judgment ofthe present inventors, is more reliable.
• PEG polyethylene glycol
• PEG-fatty acid esters have useful surfactant properties.
• PEG-fatty acid monoesters esters of lauric acid, oleic acid, and stearic acid are especially useful.
• preferred hydrophilic surfactants include PEG-8 laurate, PEG-8 oleate, PEG-8 stearate, PEG-9 oleate, PEG- 10 laurate, PEG- 10 oleate, PEG-12 laurate, PEG-12 oleate, PEG-15 oleate, PEG-20 laurate and PEG-20 oleate. Examples of polyethoxylated fatty acid monoester surfactants commercially available are shown in Table 2.
• PEG-8 oleate Mapeg® 400 MO PPG
• Emulgante A8 Condea
• Kessco PEG 400 12 MO Steppan
• Kessco® PEG 1000 MO 15 PEG-20 stearate Mapeg® 1000 MS (PPG), Kessco® PEG 1000 MS (Stepan), Myrj 16
• Polyethylene glycol (PEG) fatty acid diesters are also suitable for use as surfactants in the compositions of the present invention.
• preferred hydrophilic surfactants include PEG-20 dilaurate, PEG-20 dioleate, PEG-20 distearate, PEG-32 dilaurate and PEG-32 dioleate.
• Representative PEG-fatty acid diesters are shown in Table 3.
• Table 3 PEG-Fatty Acid Diester Surfactants
• PEG-4 dilaurate Mapeg® 200 DL PPG
• Kessco® PEG 200 DL Steppan
• LIPOPEG 7 2-DL Lipo Chem.
• PEG-8 dilaurate Mapeg® 400 DL PPG
• Kessco® PEG 400 DL Steppan
• LIPOPEG 11 4 DL LIPOPEG 11 4 DL
• mixtures of surfactants are also useful in the present invention, including mixtures of two or more commercial surfactant products.
• PEG-fatty acid esters are marketed commercially as mixtures or mono- and diesters.
• Representative surfactant mixtures are shown in Table 4.
• Suitable PEG glycerol fatty acid esters are shown in Table 5.
• preferred hydrophilic surfactants are PEG-20 glyceryl laurate, 0 PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-20 glyceryl oleate, and PEG-30 glyceryl oleate.
• a large number of surfactants of different degrees of hydrophobicity or hydrophilicity can be prepared by reaction of alcohols or polyalcohols with a variety of natural and/or hydrogenated oils.
• the oils used are castor oil or hydrogenated castor oil, or an edible vegetable oil such as corn oil, olive oil, peanut oil, palm kernel oil, apricot kernel oil, or almond oil.
• Preferred alcohols include glycerol, propylene glycol, ethylene glycol, polyethylene glycol, sorbitol, and pentaerythritol.
• preferred hydrophilic surfactants are PEG-35 castor oil (Incrocas-35), PEG-40 hydrogenated castor oil (Cremophor RH 40), PEG-25 trioleate (TAGAT® TO), PEG-60 com glycerides (Crovol M70), PEG-60 almond oil (Crovol A70), PEG-40 palm kernel oil (Crovol PK70), PEG-50 castor oil (Emalex C- 50), PEG-50 hydrogenated castor oil (Emalex HC-50), PEG-8 caprylic/capric glycerides (Labrasol), and PEG-6 caprylic/capric glycerides (Softigen 767).
• Preferred hydrophobic surfactants in this class include PEG-5 hydrogenated castor oil, PEG-7 hydrogenated castor oil, PEG-9 hydrogenated castor oil, PEG-6 com oil (Labrafil® M 2125 CS), PEG-6 almond oil (Labrafil® M 1966 CS), PEG-6 apricot kernel oil (Labrafil® M 1944 CS), PEG-6 olive oil (Labrafil® M 1980 CS), PEG-6 peanut oil (Labrafil® M 1969 CS), PEG- 6 hydrogenated palm kernel oil (Labrafil® M 2130 BS), PEG-6 palm kernel oil (Labrafil® M 2130 CS), PEG-6 triolein (Labrafil® M 2735 CS), PEG-8 com oil (Labrafil® WL 2609 BS), PEG-20 com glycerides (Crovol M40), and PEG-20 almond glycerides (Crovol A40).
• PEG-40 hydrogenated castor oil Cremophor RH 40 (BASF), Croduret (Croda), Emulgin HRE 40 13 (Henkel)
• PEG-8 caprylic/capric glycerides Labrasol (Gattefosse),Labrafac CM 10 (Gattefosse) >10
• Pentaerythrityl Liponate PE-810 (Lipo Chem.), Crodamol PTC (Croda) ⁇ 10 tetracaprylate/tetracaprate
• oils in this category of surfactants are oil-soluble vitamins, such as vitamins A, D, E, K, etc.
• derivatives of these vitamins such as tocopheryl PEG- 15 1000 succinate (TPGS, available from Eastman), are also suitable surfactants.
• TPGS tocopheryl PEG- 15 1000 succinate
• Polyglycerol esters of fatty acids are also suitable surfactants for the present invention.
• preferred hydrophobic surfactants include polyglyceryl oleate (Plurol Oleique), polyglyceryl-2 dioleate (Nikkol DGDO), and 0 polyglyceryl-10 trioleate.
• Preferred hydrophilic surfactants include polyglyceryl-10 laurate (Nikkol Decaglyn 1-L), polyglyceryl-10 oleate (Nikkol Decaglyn l-O), and polyglyceryl-10 mono, dioleate (Caprol® PEG 860).
• Polyglyceryl polyricinoleates Polymuls
• Examples of suitable polyglyceryl esters are shown in Table 7. 5
• Polyglyceryl-6 pentaoleate Nikkol Hexaglyn 5-0 (Nikko) ⁇ 10 Polyglyceryl-3 dioleate Cremophor G032 (BASF) ⁇ 10 Polyglyceryl-3 distearate Cremophor GS32 (BASF) ⁇ 10 Polyglyceryl-4 pentaoleate Nikkol Tetraglyn 5-0 (Nikko) ⁇ 10 Polyglyceryl-6 dioleate Caprol® 6G20 (ABITEC); Hodag PGO-62 (Calgene), PLUROL 8.5 OLEIQUE CC 497 (Gattefosse)
• esters of propylene glycol and fatty acids are suitable surfactants for use in the present invention.
• preferred hydrophobic surfactants include propylene glycol monolaurate (Lauroglycol FCC), propylene glycol ricinoleate (Propymuls), propylene glycol monooleate (Myverol P-O6), propylene glycol dicaprylate/dicaprate (Captex® 200), and propylene glycol dioctanoate (Captex® 800). Examples of surfactants of this class are given in Table 8.
• Propylene glycol LABRAFAC PG (Gattefosse) >6 caprylate/caprate Propylene glycol dilaurate >6 Propylene glycol distearate Kessco® PGDS (Stepan) >6 Propylene glycol dicaprylate Nikkol Sefsol 228 (Nikko) >6 Propylene glycol dicaprate Nikkol PDD (Nikko) >6
• mixtures of surfactants are also suitable for use in the present invention.
• mixtures of propylene glycol fatty acid esters and glycerol fatty acid esters are suitable and are commercially available.
• One preferred mixture is composed of the oleic acid esters of propylene glycol and glycerol (Arlacel 186). Examples of these surfactants are shown in Table 9.
• a particularly important class of surfactants is the class of mono- and diglycerides.
• surfactants are generally hydrophobic.
• Preferred hydrophobic surfactants in this class of compounds include glyceryl monooleate (Peceol), glyceryl ricinoleate, glyceryl laurate, glyceryl dilaurate (Capmul® GDL), glyceryl dioleate (Capmul® GDO), glyceryl mono/dioleate (Capmul® GMO-K), glyceryl caprylate/caprate (Capmul® MCM), caprylic acid mono/diglycerides (Imwitor® 988), and mono- and diacetylated monoglycerides
• Glyceryl monooleate C 18 : 1
• PECEOL Geattefosse
• Hodag GMO-D Hodag GMO-D
• Nikkol MGO Nikko
• Glyceryl monooleate RYLO series (Danisco), DIMODAN series (Danisco), EMULDAN 3-4 (Danisco), ALDO® MO FG (Lonza), Kessco GMO (Stepan), MONOMULS® series (Henkel), TEGIN O, DREWMULSE GMO (Stepan), Atlas G-695 (ICI), GMOrphic 80 (Eastman), ADM DMG-40, 70, and 100 (ADM), Myverol (Eastman)
• Glycerol monolinoleate Maisine (Gattefosse), MYVEROL 18-92, Myverol 18-06 (Eastman) 3-4
• Glyceryl ricinoleate Softigen® 701 Hiils
• HODAG GMR-D Calgene
• Glycerol monostearate Capmul® GMS (ABITEC), Myvaplex (Eastman), IMWITOR® 191 5-9 (H ⁇ ls), CUTINA GMS, Aldo® MS (Lonza), Nikkol MGS series (Nikko)
• Glyceryl acetate Lamegin® EE (Griinau GmbH) ⁇ 10 Glyceryl laurate Imwitor® 312 (H ⁇ ls), Monomuls® 90-45 (Gr ⁇ nau GmbH), Aldo® MLD (Lonza)
• Glyceryl caprylate Imwitor® 308 H ⁇ ls
• Capmul® MCMC8 (ABITEC) 5-6
• Lactic acid esters of LAMEGIN GLP (Henkel) ⁇ 10 mono,diglycerides
• Glycerol esters of fatty acids GELUCIRE 39/01 (Gattefosse), GELUCIRE 43/01 (Gattefosse) 1
• Sterols and derivatives of sterols are suitable surfactants for use in the present invention. These surfactants can be hydrophilic or hydrophobic. Preferred derivatives include the polyethylene glycol derivatives. A preferred hydrophobic surfactant in this class is cholesterol. A preferred hydrophilic surfactant in this class is PEG-24 cholesterol
• PEG-sorbitan fatty acid esters are available and are suitable for use as surfactants in the present invention.
• these surfactants are hydrophilic, although several hydrophobic surfactants of this class can be used.
• preferred hydrophilic surfactants include PEG-20 sorbitan monolaurate
• Tween-20 PEG-20 sorbitan monopalmitate (Tween-40), PEG-20 sorbitan monostearate (Tween-60), and PEG-20 sorbitan monooleate (Tween-80).
• Tween-20 PEG-20 sorbitan monopalmitate
• Tween-60 PEG-20 sorbitan monostearate
• Tween-80 PEG-20 sorbitan monooleate
• Ethers of polyethylene glycol and alkyl alcohols are suitable surfactants for use in the present invention.
• Preferred hydrophobic ethers include PEG-3 oleyl ether (Volpo 3) and PEG-4 lauryl ether (Brij 30). Examples of these surfactants are shown in Table 13.
• esters of sugars are suitable surfactants for use in the present invention.
• Preferred hydrophilic surfactants in this class include sucrose monopalmitate and sucrose monolaurate. Examples of such surfactants are shown in Table 14.
• Sucrose distearate SUCRO ESTER 7 (Gattefosse), Crodesta F- 10 (Croda) 3
• Sucrose distearate/monostearate SUCRO ESTER 11 (Gattefosse), Crodesta F-l 10 (Croda) 12 Sucrose dipalmitate 7.4
• hydrophilic PEG-alkyl phenol surfactants are available, and are suitable for use in the present invention. Examples of these surfactants are shown in Table 15.
• the POE-POP block copolymers are a unique class of polymeric surfactants.
• the unique stmcture of the surfactants, with hydrophilic POE and hydrophobic POP moieties in well-defined ratios and positions, provides a wide variety of surfactants suitable for use in the present invention.
• These surfactants are available under various trade names, including Synperonic PE series (ICI); Pluronic® series (BASF), Emkalyx, Lutrol (BASF),
• polystyrene resin (CAS 9003-11-6). These polymers have the formula:
• Preferred hydrophilic surfactants of this class include Poloxamers 108, 188, 217,
• hydrophobic surfactants in this class include
• Poloxamers 124, 182, 183, 212, 331, and 335 examples of suitable surfactants of this class are shown in Table 16. Since the compounds are widely available, commercial sources are not listed in the Table. The compounds are listed by generic name, with the corresponding "a" and "b" values.
• Sorbitan Fatty Acid Esters Sorbitan esters of fatty acids are suitable surfactants for use in the present invention. Among these esters, preferred hydrophobic surfactants include sorbitan monolaurate (Arlacel 20), sorbitan monopalmitate (Span-40), sorbitan monooleate (Span- 80), sorbitan monostearate, and sorbitan tristearate. Examples of these surfactants are shown in Table 17.
• Sorbitan monolaurate Span-20 (Atlas/ICI), Crill 1 (Croda), Arlacel 20 (ICI) 8.6 Sorbitan monopalmitate Span-40 (Atlas/ICI), Crill 2 (Croda), Nikkol SP-10 (Nikko) 6.7
• Sorbitan monostearate Span-60 (Atlas/ICI), Crill 3 (Croda), Nikkol SS-10 (Nikko) 4.7
• Sorbitan sesquioleate Arlacel-C (ICI), Crill 43 (Croda), Nikkol SO- 15 (Nikko) 3.7
• Esters of lower alcohols (C to C 4 ) and fatty acids (C 8 to 8 ) are suitable surfactants for use in the present invention.
• preferred hydrophobic surfactants include ethyl oleate (Crodamol EO), isopropyl myristate (Crodamol IPM), and isopropyl palmitate (Crodamol IPP). Examples of these surfactants are shown in Table 18.
• Ionic surfactants including cationic, anionic and zwitterionic surfactants, are suitable hydrophilic surfactants for use in the present invention.
• Preferred anionic surfactants include fatty acid salts and bile salts.
• Preferred cationic surfactants include carnitines.
• preferred ionic surfactants include sodium oleate, sodium lauryl sulfate, sodium lauryl sarcosinate, sodium dioctyl sulfosuccinate, sodium cholate, sodium taurocholate; lauroyl camitine; palmitoyl camitine; and myristoyl camitine. Examples of such surfactants are shown in Table 19. For simplicity, typical counterions are shown in the entries in the Table.
• any bioacceptable counterion may be used.
• the fatty acids are shown as sodium salts, other cation counterions can also be used, such as alkali metal cations or ammonium.
• these ionic surfactants are generally available as pure compounds, rather than commercial (proprietary) mixtures. Because these compounds are readily available from a variety of commercial suppliers, such as Aldrich, Sigma, and the like, commercial sources are not generally listed in the Table.
• Ether carboxylates (by oxidation of terminal OH group of fatty alcohol ethoxylates)
• Citric acid esters of mono-, diglycerides are Citric acid esters of mono-, diglycerides
• Acyl lactylates lactylic esters of fatty acids calcium/sodium stearoyl-2-lactylate calcium/sodium stearoyl lactylate r.p. Alginate salts
• Betaines (trialkylglycine):
• Ionizable surfactants when present in their unionized (neutral, non-salt) form, are hydrophobic surfactants suitable for use in the compositions and methods of the present invention.
• Particular examples of such surfactants include free fatty acids, particularly C 6 - C 22 fatty acids, and bile acids.
• suitable unionized ionizable surfactants include the free fatty acid and bile acid forms of any of the fatty acid salts and bile salts shown in Table 19.
• the carrier includes at least one hydrophilic surfactant.
• Preferred non-ionic hydrophilic surfactants include alkylglucosides; alkylmaltosides; alkylthioglucosides; lauryl macrogolglycerides; polyoxyethylene alkyl ethers; polyoxyethylene alkylphenols; polyethylene glycol fatty acids esters; polyethylene glycol glycerol fatty acid esters; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene- polyoxypropylene block copolymers; polyglycerol fatty acid esters; polyoxyethylene glycerides; polyoxyethylene sterols, derivatives, and analogues thereof; polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils; reaction mixtures of polyols with fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols; sugar esters, sugar ethers; sucroglycerides
• the non-ionic hydrophilic surfactant is selected from the group consisting of polyoxyethylene alkylethers; polyethylene glycol fatty acids esters; polyethylene glycol glycerol fatty acid esters; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene-polyoxypropylene block copolymers; polyglyceryl fatty acid esters; polyoxyethylene glycerides; polyoxyethylene vegetable oils; and polyoxyethylene hydrogenated vegetable oils.
• the glyceride can be a monoglyceride, diglyceride, triglyceride, or a mixture.
• non-ionic hydrophilic surfactants that are reaction mixtures of polyols and fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils or sterols. These reaction mixtures are largely composed of the transesterification products of the reaction, along with often complex mixtures of other reaction products.
• the polyol is preferably glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, or a saccharide.
• carrier compositions are those which include as a non-ionic hydrophilic surfactant PEG- 10 laurate, PEG-12 laurate, PEG-20 laurate, PEG- 32 laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, PEG-32 distearate, PEG-40 stearate, PEG- 100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 glyceryl
• PEG-20 laurate PEG-20 oleate
• PEG-35 castor oil PEG-40 palm kernel oil
• PEG-40 hydrogenated castor oil PEG- 60 com oil
• PEG-25 glyceryl trioleate polyglyceryl-10 laurate
• PEG-6 caprate/caprylate glycerides PEG-8 caprate/caprylate glycerides
• PEG-30 cholesterol polysorbate 20
• polysorbate 80 POE-9 lauryl ether
• POE-23 lauryl ether POE- 10 oleyl ether
• PEG-24 cholesterol sucrose monostearate
• sucrose monolaurate and poloxamers PEG-20 laurate
• PEG-40 hydrogenated castor oil PEG- 60 com oil
• PEG-25 glyceryl trioleate polyglyceryl-10 laurate
• PEG-6 caprate/caprylate glycerides PEG-8
• PEG-35 castor oil PEG-40 hydrogenated castor oil, PEG-60 com oil, PEG-25 glyceryl trioleate, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, polysorbate 20, polysorbate 80, tocopheryl PEG-1000 succinate, PEG-24 cholesterol, and hydrophilic poloxamers.
• the hydrophilic surfactant can also be, or include as a component, an ionic surfactant.
• Preferred ionic surfactants include alkyl ammonium salts; bile acids and salts, analogues, and derivatives thereof; fusidic acid and derivatives thereof; fatty acid derivatives of amino acids, ohgopeptides, and polypeptides; glyceride derivatives of amino acids, ohgopeptides, and polypeptides; acyl lactylates; mono-,diacetylated tartaric acid esters of mono-,diglycerides; succinylated monoglycerides; citric acid esters of mono- jdiglycerides; alginate salts; propylene glycol alginate; lecithins and hydrogenated lecithins; lysolecithin and hydrogenated lysolecithins; lysophospholipids and derivatives thereof; phospholipids and derivatives thereof; salts of alky
• More preferable ionic surfactants include bile acids and salts, analogues, and derivatives thereof; lecithins, lysolecithin, phospholipids, lysophospholipids and derivatives thereof; salts of alkylsulfates; salts of fatty acids; sodium docusate; acyl lactylates; mono-,diacetylated tartaric acid esters of mono-,diglycerides; succinylated monoglycerides; citric acid esters of mono-,diglycerides; camitines; and mixtures thereof.
• prefe ⁇ ed ionic surfactants are lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, lysophosphatidylserine, PEG- phosphatidylethanolamine, PVP-phosphatidylethanolamine, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, cholate, taurocholate, glycocholate, deoxycholate, tau
• Particularly prefe ⁇ ed ionic surfactants are lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, lysophosphatidylcholine, PEG-phosphatidylethanolamine, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, cholate, taurocholate, glycocholate, deoxycholate, taurodeoxycholate, glycodeoxycholate, cholylsarcosine, caproate, caprylate, caprate, laurate, oleate, lauryl sulfate, docusate, and salts and mixtures thereof, with the most preferred ionic surfactants being le
• the carrier of the present compositions includes at least two surfactants, at least one of which is hydrophilic.
• the present invention includes at two surfactants that are hydrophilic, and preferred hydrophilic surfactants are listed above.
• the carrier includes at least one hydrophilic surfactant and at least one hydrophobic surfactant.
• preferred hydrophobic surfactants are alcohols; polyoxyethylene alkylethers; fatty acids; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acids esters; polyethylene glycol fatty acids esters; polyethylene glycol glycerol fatty acid esters; polypropylene glycol fatty acid esters; polyoxyethylene glycerides; lactic acid derivatives of mono/diglycerides; propylene glycol diglycerides; sorbitan fatty acid esters; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene-polyoxypropylene block copolymers; transesterified vegetable oils; sterols; sterol derivatives; sugar esters; sugar ethers; sucroglycerides; polyoxyethylene vegetable oils; and polyoxyethylene hydrogenated vegetable oils.
• hydrophobic surfactants can be reaction mixtures of polyols and fatty acids, glycer
• the hydrophobic surfactant is selected from the group consisting of fatty acids; lower alcohol fatty acid esters; polyethylene glycol glycerol fatty acid esters; polypropylene glycol fatty acid esters; polyoxyethylene glycerides; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lactic acid derivatives of mono/diglycerides; sorbitan fatty acid esters; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene- polyoxypropylene block copolymers; polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils; and reaction mixtures of polyols and fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols.
• lower alcohol fatty acids esters More preferred are lower alcohol fatty acids esters; polypropylene glycol fatty acid esters; propylene glycol fatty acid esters; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lactic acid derivatives of mono/diglycerides; sorbitan fatty acid esters; polyoxyethylene vegetable oils; and mixtures thereof, with glycerol fatty acid esters and acetylated glycerol fatty acid esters being most preferred.
• the esters are preferably mono- or diglycerides, or mixtures of mono- and diglycerides, where the fatty acid moiety is a C 6 to C 22 fatty acid.
• hydrophobic surfactants which are the reaction mixture of polyols and fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols.
• Preferred polyols are polyethylene glycol, sorbitol, propylene glycol, and pentaerythritol.
• hydrophobic surfactants include myristic acid; oleic acid; lauric acid; stearic acid; palmitic acid; PEG 1-4 stearate; PEG 2-4 oleate; PEG-4 dilaurate; PEG-4 dioleate; PEG-4 distearate; PEG-6 dioleate; PEG-6 distearate; PEG-8 dioleate; PEG 3-16 castor oil; PEG 5-10 hydrogenated castor oil; PEG 6-20 com oil; PEG 6-20 almond oil; PEG-6 olive oil; PEG-6 peanut oil; PEG-6 palm kernel oil; PEG-6 hydrogenated palm kernel oil; PEG-4 capric/caprylic triglyceride, mono, di, tri, tetra esters of vegetable oil and sorbitol; pentaerythrityl di, tetra stearate, isostearate, oleate, caprylate, or caprate; polyglyceryl 2-4 oleate
• hydrophobic surfactants most preferred are oleic acid; lauric acid; glyceryl monocaprate; glyceryl monocaprylate; glyceryl monolaurate; glyceryl monooleate; glyceryl dicaprate; glyceryl dicaprylate; glyceryl dilaurate; glyceryl dioleate; acetylated monoglycerides; propylene glycol oleate; propylene glycol laurate; polyglyceryl-3 oleate; polyglyceryl-6 dioleate; PEG-6 com oil; PEG-20 com oil; PEG-20 almond oil; sorbitan monooleate; sorbitan monolaurate; POE-4 lauryl ether; POE-3 oleyl ether; ethyl oleate; and poloxamers. 3. Therapeutic Agents
• the therapeutic agents suitable for use in the pharmaceutical compositions and methods of the present invention are not particularly limited, as the compositions are surprisingly capable of solubilizing and delivering a wide variety of therapeutic agents.
• the therapeutic agents can be hydrophilic, lipophilic, amphiphilic or hydrophobic, and can be solubilized in the triglyceride; solubilized in the carrier; solubilized in both the triglyceride and the carrier; or present in the diluent.
• the therapeutic agent can be present in a first, solubilzed amount, and a second, non-solubilized (suspended) amount.
• Such therapeutic agents can be any agents having therapeutic or other value when administered to an animal, particularly to a mammal, such as drugs, nutrients, and cosmetics (cosmeceuticals). It should be understood that while the invention is described with particular reference to its value in the form of aqueous dispersions, the invention is not so limited. Thus, dmgs, nutrients or cosmetics which derive their therapeutic or other value from, for example, topical or transdermal administration, are still considered to be suitable for use in the present invention.
• therapeutic agents that can be used in the pharmaceutical compositions of the present invention include analgesics and anti- inflammatory agents, anthelmintics, anti-arrhythmic agents, anti-asthma agents, antibacterial agents, anti-viral agents, anti-coagulants, anti-depressants, anti-diabetics, anti-
• the therapeutic agent is a nutritional agent. In another embodiment, the therapeutic agent is a cosmeceutical agent.
• the therapeutic agent is a protein, peptide or oligonucleotide.
• the therapeutic agent is a protein, peptidomimetic, DNA, RNA, ohgodeoxynucleotide, genetic material, peptide or oligonucleotide having a molecular weight of less than about 1000 g/mol.
• the therapeutic agent is hydrophobic. Hydrophobic therapeutic agents are compounds with little or no water solubility. Intrinsic water solubilities (i.e., water solubility of the unionized form) for hydrophobic therapeutic agents are less than about 1% by weight, and typically less than about 0.1% or 0.01% by weight. In a particular aspect of this embodiment, the therapeutic agent is a hydrophobic
• the therapeutic agent is a hydrophobic dmg having a molecular weight of less than about 1000 g/mol.
• the therapeutic agent is hydrophilic.
• Amphiphilic therapeutic agents are included within the class of hydrophilic therapeutic agents.
• Apparent water solubilities for hydrophilic therapeutic agents are greater than about 1% by
• the therapeutic agent is a hydrophilic dmg.
• the therapeutic agent is a hydrophilic dmg having a molecular weight of less than about 1000 g/mol.
• therapeutic agents suitable for use in the compositions and methods of the present invention include the following representative compounds, as well as their pharmaceutically acceptable salts, isomers, esters, ethers and other derivatives: abacavir, acarbose, acebutolol, acetazolamide, acetohexamide, acrivastine, acutretin, acyclovir, alatrofloxacin, albendazole, albuterol, alclofenac, alendronate, allopurinol, aloxiprin, alprazolam, alprenolol, alprostadil, amantadine, amiloride, aminoglutethimide, amiodarone, amiodarone HCl, amitriptyline, amlodipine, , amodiaquine, amoxapine, amoxapine, amphetamine, amphotericin, amprenavir, amrinone
• the components of the pharmaceutical compositions of the present invention in amounts such that upon dilution with an aqueous solution, the composition forms a clear, aqueous dispersion.
• concentrations of components to form clear aqueous dispersions are the concentrations of triglyceride and surfactants, with the amount of the therapeutic agent, if present, being chosen as described below.
• the relative amounts of triglycerides and surfactants are readily determined by observing the properties of the resultant dispersion; i.e., when the relative amounts of these components are within a suitable range, the resultant aqueous dispersion is optically clear.
• the resulting dispersion is visibly "cloudy", resembling a conventional emulsion or multiple-phase system.
• a visibly cloudy solution may be potentially useful for some applications, such a system would suffer from many of the same disadvantages as conventional prior art formulations, as described above.
• a convenient method of determining the appropriate relative concentrations for any particular triglyceride is as follows. A convenient working amount of a hydrophilic surfactant is provided, and a known amount of the triglyceride is added. The mixture is sti ⁇ ed, with the aid of gentle heating if desired, then is diluted with purified water to prepare an aqueous dispersion. Any dilution amount can be chosen, but convenient dilutions are those within the range expected in vivo, about a 10 to 250-fold dilution. In the Examples herein, a convenient dilution of 100-fold was chosen. The aqueous dispersion is then assessed qualitatively for optical clarity.
• the procedure can be repeated with incremental variations in the relative amount of triglyceride added, to determine the maximum relative amount of triglyceride that can be present to form a clear aqueous dispersion with a given hydrophilic surfactant. I.e., when the relative amount of triglyceride is too great, a hazy or cloudy dispersion is formed.
• the amount of triglyceride that can be solubilized in a clear aqueous dispersion is increased by repeating the above procedure, but substituting a second hydrophilic surfactant, or a hydrophobic surfactant, for part of the originally-used hydrophilic surfactant, thus keeping the total surfactant concentration constant.
• a second hydrophilic surfactant or a hydrophobic surfactant, for part of the originally-used hydrophilic surfactant, thus keeping the total surfactant concentration constant.
• this procedure is merely exemplary, and the amounts of the components can be chosen using other methods, as desired.
• mixtures of surfactants including two hydrophilic surfactants can solubilize a greater relative amount of triglyceride than a single surfactant.
• mixtures of surfactants including a hydrophilic surfactant and a hydrophobic surfactant can solubilize a greater relative amount of triglyceride than either surfactant by itself. It is particularly surprising that when the surfactant mixture includes a hydrophilic surfactant and a hydrophobic surfactant, the solubility of the triglyceride is greater than, for example, in the hydrophilic surfactant itself.
• 4,719,239 shows optically clear compositions containing water, oil, and a 3:7 mixture of PEG-glycerol monooleate and caprylic-capric acid glycerol esters, but the compositions contain no more that about 75% by weight water, or a dilution of the pre- concentrate of no more than 3 to 1.
• the compositions of the cited reference phase-separate into multi-phase systems as is shown, for example, in the phase diagram of Figure 2 in the '239 patent.
• compositions of the present invention when diluted to values typical of dilutions encountered in vivo, or when diluted in vivo upon administration to a patient, remain as clear aqueous dispersions.
• the clear aqueous dispersions ofthe present invention are formed upon dilution of about 10 to about 250- fold or more.
• the optical clarity of the aqueous dispersion can be measured using standard quantitative techniques for turbidity assessment.
• One convenient procedure to measure turbidity is to measure the amount of light of a given wavelength transmitted by the solution, using, for example, a UV-visible spectrophotometer. Using this measure, optical clarity corresponds to high transmittance, since cloudier solutions will scatter more ofthe incident radiation, resulting in lower transmittance measurements. If this procedure is used, care should be taken to insure that the composition itself does not absorb light of the chosen wavelength, as any tme absorbance necessarily reduces the amount of transmitted light and falsely increases the quantitative turbidity value.
• suitable dispersions at a dilution of 100X should have an apparent absorbance of less than about 0.3, preferably less than about 0.2, and more preferably less than about 0.1.
• optical clarity such as direct particle size measurement and other methods known in the art may also be used.
• the therapeutic agent is solubilized in the triglyceride, the carrier, or in both the triglyceride and the carrier.
• the therapeutic agent can be solubilized in the aqueous medium used to dilute the preconcentrate to form an aqueous dispersion.
• the maximum amount of therapeutic agent that can be solubilized is readily determined by simple mixing, as the presence of any non-solubilized therapeutic agent is apparent upon visual examination.
• the therapeutic agent is present in an amount up to the maximum amount that can be solubilized in the composition.
• the therapeutic agent is present in a first amount which is solubilized, and a second amount that remains unsolubilized but dispersed. This may be desirable when, for example, a larger dose of the therapeutic agent is desired.
• a composition presents advantages over conventional compositions, since at least a portion of the therapeutic agent is present in the clear aqueous dispersion phase.
• the optical clarity of the resultant aqueous dispersion is determined before the second non-solubilized amount ofthe therapeutic agent is added.
• the pharmaceutical compositions of the present invention can optionally include additional compounds to enhance the solubility of the therapeutic agent or the triglyceride in the composition.
• additional compounds include: 0 alcohols and polyols, such as ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediols and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives; 5 ethers of polyethylene glycols having an average molecular weight of about 200 to about 6000, such as tetrahydrofurfuryl alcohol PEG ether (glycofur
• solubilizers are also within the scope of the invention. Except as indicated, these compounds are readily available from standard commercial sources.
• Prefe ⁇ ed solubilizers include triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrins, ethanol, polyethylene glycol 200-600, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide.
• Particularly preferred solubilizers include sorbitol, glycerol, triacetin, ethyl alcohol, PEG-400, glycofurol and propylene glycol.
• the amount of solubilizer that can be included in compositions of the present invention is not particularly limited.
• the amount of a given solubilizer is limited to a bioacceptable amount, which is readily determined by one of skill in the art.
• the solubilizer can be in a concentration of 50%, 100%, 200%, or up to about 400% by weight, based on the amount of surfactant.
• solubilizers may also be used, such as 25%, 10%, 5%, 1% or even less.
• solubilizer will be present in an amount of about 1% to about 100%, more typically about 5% to about 25% by weight or about 10% to about 25%o by weight.
• the compositions can include an enzyme inhibiting agent.
• Enzyme inhibiting agents are shown for example, in Bemskop-Schnurch, A., "The use of inhibitory agents to overcome enzymatic barrier to perorally administered therapeutic peptides and proteins", J. Controlled Release 52, 1-16 (1998), the disclosure of which is incorporated herein by reference.
• inhibitory agents can be divided into the following classes: Inhibitors that are not based on amino acids, such as P-aminobenzamidine, FK- 448, camostat mesylate, sodium glycocholate;
• Amino acids and modified amino acids such as aminoboronic acid derivatives and n-acetylcysteine
• Peptides and modified peptides such as bacitracin, phosphinic acid dipeptide derivatives, pepstatin, antipain, leupeptin, chymostatin, elastatin, bestatin, hosphoramindon, puromycin, cytochalasin potatocarboxy peptidase inhibitor, and amastatin;
• Polypeptide protese inhibitors such as aprotinin (bovine pancreatic trypsin inhibitor), Bowman-Birk inhibitor and soybean trypsin inhibitor, chicken egg white trypsin inhibitor, chicken ovoinhibitor, and human pancreatic trypsin inhibitor.
• Complexing agents such as EDTA, EGTA, 1,10- phenanthroline and hydroxychinoline;
• Mucoadhesive polymers and polymer-inhibitor conjugates such as polyacrylate derivatives, chitosan, cellulosics, chitosan-EDTA, chitosan-EDTA-antipain, polyacrylic acid-bacitracin, carboxymethyl cellulose-pepstatin, polyacrylic acid-B woman-Birk inhibitor.
• the choice and levels of the enzyme inhibitor are based on toxicity, specificity of the proteases and the potency of the inhibition.
• the inhibitor can be suspended or solubilized in the composition preconcentrate, or added to the aqueous diluent or as a beverage.
• an inhibitor can function solely or in combination as: a competitive inhibitor, by binding at the substrate binding site of the enzyme, thereby preventing the access to the substrate; examples of inhibitors believed to operate by this mechanism are antipain, elastatinal and the Bowman Birk inhibitor; a non-competitive inhibitor which can be simultaneously bound to the enzyme site along with the substrate, as their binding sites are not identical; and/or a complexing agent due to loss in enzymatic activity caused by deprivation of essential metal ions out ofthe enzyme stmcture. 7.
• a competitive inhibitor by binding at the substrate binding site of the enzyme, thereby preventing the access to the substrate
• examples of inhibitors believed to operate by this mechanism are antipain, elastatinal and the Bowman Birk inhibitor
• a non-competitive inhibitor which can be simultaneously bound to the enzyme site along with the substrate, as their binding sites are not identical
• a complexing agent due to loss in enzymatic activity caused by deprivation of essential metal ions out ofthe enzyme s
• additives conventionally used in pharmaceutical compositions can be included, and these additives are well known in the art.
• additives include detackifiers, anti-foaming agents, buffering agents, antioxidants, preservatives, chelating agents, viscomodulators, tonicifiers, flavorants, colorants odorants, opacifiers, suspending agents, binders, fillers, plasticizers, lubricants, and mixtures thereof.
• the amounts of such additives can be readily determined by one skilled in the art, according to the particular properties desired. 8. Dosage Forms
• compositions of the present invention can be formulated as a preconcentrate in a liquid, semi-solid, or solid form, or as an aqueous or organic diluted preconcentrate.
• the diluent can be water, an aqueous solution, a buffer, an organic solvent, a beverage, a juice, or mixtures thereof.
• the diluent can include components soluble therein, such as a therapeutic agent, an enzyme inhibitor, solubilizers, additives, and the like.
• compositions can be processed according to conventional processes known to those skilled in the art, such as lyophilization, encapsulation, compression, melting, extmsion, drying, chilling, molding, spraying, coating, comminution, mixing, homogenization, sonication and granulation, to produce the desired dosage form.
• compositions of the present invention can be formulated as pills, capsules, caplets, tablets, granules, beads or powders. Granules, beads and powders can, of course, be further processed to form pills, capsules, caplets or tablets.
• the capsule can be a hard or soft gelatin capsule, a starch capsule, or a cellulosic capsule.
• Such dosage forms can further be coated with, for example, a seal coating or an enteric coating.
• enteric coated capsule as used herein means a capsule coated with a coating resistant to acid; i.e., an acid resistant enteric coating.
• Enteric coated compositions of this invention protect therapeutic peptides or proteins in a restricted area of dmg liberation and absorption, and reduce or even exclude extensive dilution effects.
• solubilizers are typically used to enhance the solubility of a hydrophobic therapeutic agent, they may also render the compositions more suitable for encapsulation in hard or soft gelatin capsules.
• a solubilizer such as those described above is particularly preferred in capsule dosage forms of the pharmaceutical compositions. If present, these solubilizers should be added in amounts sufficient to impart to the compositions the desired solubility enhancement or encapsulation properties.
• compositions of the present invention can also be formulated for topical, transdermal, buccal, ocular, pulmonary, vaginal, rectal, transmucosal or parenteral administration, as well as for oral administration.
• the dosage form can be a solution, suspension, emulsion, cream, ointment, lotion, suppository, spray, aerosol, paste, gel, drops, douche, ovule, wafer, troche, cachet, symp, elixer, or other dosage form, as desired. If formulated as a suspension, the composition can further be processed in capsule form.
• a dosage form of a multiparticulate carrier coated onto a substrate with the pharmaceutical compositions described herein can be used.
• the substrate can be a granule, a particle, or a bead, for example, and formed of a therapeutic agent or a pharmaceutically acceptable material.
• the multiparticulate carrier can be enteric coated with a pharmaceutically acceptable material as is well known to those skilled in the art.
• the triglyceride and surfactants are present in amounts such that upon mixing with an aqueous solution, either in vitro or in vivo, a clear, aqueous dispersion is formed.
• This optical clarity in an aqueous dispersion defines the appropriate relative concentrations of the triglyceride and surfactant components, but does not restrict the dosage form of the compositions to an aqueous dispersion, nor does it limit the compositions of the invention to optically clear dosage forms.
• the appropriate concentrations of the triglyceride and surfactants are determined by the optical clarity of a dispersion formed by the composition preconcentrate and an aqueous solution in a dilution of about 10 to about 250-fold, as a preliminary matter.
• the pharmaceutical compositions can be formulated as described in the preceding section, without regard to the optical clarity of the ultimate formulation.
• optically clear aqueous dispersions, and their preconcentrates are preferred formulations.
• the present invention relates to pharmaceutical compositions having a triglyceride and a carrier, the carrier including at least two surfactants, at least one of which is hydrophilic.
• the triglyceride and surfactants are present in amounts such that upon mixing with an aqueous solution, either in vitro or in vivo, the composition forms a clear aqueous dispersion.
• the composition can contain more triglyceride than can be solubilized in a clear aqueous dispersion having only one surfactant, the surfactant being hydrophilic.
• this embodiment provides a higher concentration of triglyceride than is achievable with a single hydrophilic surfactant, resulting in a reduced triglyceride to hydrophilic surfactant ratio and enhanced biocompatibility.
• the present invention relates to pharmaceutical compositions having a triglyceride and a carrier, the carrier including at least one hydrophilic surfactant and at least one hydrophobic surfactant.
• the triglyceride and surfactants are present in amounts such that upon mixing with an aqueous solution, either in vitro or in vivo, the composition forms a clear aqueous dispersion.
• the composition contains more triglyceride than can be solubilized in a clear aqueous dispersion having a hydrophilic surfactant but not having a hydrophobic surfactant..
• the triglyceride itself can have therapeutic value as, for example, a nutritional oil, or absorption-promoting value as, for example, a long-chain triglyceride (LCT) or a medium-chain triglyceride (MCT).
• a triglyceride having nutritional and/or absorption-promoting value and a carrier.
• the carrier includes at least two surfactants, at least one of which is hydrophilic.
• the carrier can include at least one hydrophilic surfactant and at least one hydrophobic surfactant.
• the present invention relates to a pharmaceutical composition which includes a therapeutic agent, a triglyceride and a carrier.
• the carrier includes at least two surfactants, at least one of which is hydrophilic.
• the carrier includes at least one hydrophilic surfactant and at least one hydrophobic surfactant.
• the triglyceride, and surfactants are present in amounts such that upon dilution with an aqueous solution, either in vitro or in vivo, the composition forms a clear aqueous dispersion.
• the therapeutic agent is present in two amounts, a first amount of the therapeutic agent solubilized in the clear aqueous dispersion, and a second amount of the therapeutic agent that remains non-solubilized but dispersed.
• the present invention relates to triglyceride-containing pharmaceutical compositions as described in the preceding embodiments, which further include a therapeutic agent.
• the therapeutic agent is a hydrophobic drug or a hydrophilic dmg.
• the therapeutic agent is a nutritional agent.
• the therapeutic agent is a cosmeceutical agent.
• compositions of the present invention can be prepared by conventional methods well known to those skilled in the art. Of course, the specific method of preparation will depend upon the ultimate dosage form.
• dosage forms substantially free of water i.e., when the composition is provided in a pre-concentrate form for later dispersion in vitro or in vivo in an aqueous system, the composition is prepared by simple mixing of the components to form a pre-concentrate. The mixing process can be aided by gentle heating, if desired.
• the pre-concentrate form is prepared, then the appropriate amount of an aqueous solution is added. Upon gentle mixing, a clear aqueous dispersion is formed.
• any water-soluble enzyme inhibitors or additives may be included, these may be added first as part of the pre-concentrate, or added later to the clear aqueous dispersion, as desired.
• the compositions can be prepared with or without a therapeutic agent, and a therapeutic agent may also be provided in the diluent, if desired.
• the present invention includes a multi-phase dispersion containing a therapeutic agent.
• a pharmaceutical composition includes a triglyceride and a carrier, which forms a clear aqueous dispersion upon mixing with an aqueous solution, and an additional amount of non-solubilized therapeutic agent.
• multi-phase as used herein to describe these compositions of the present invention means a composition which when mixed with an aqueous solution forms a clear aqueous phase and a particulate dispersion phase.
• the carrier and triglycerides are as described above, and can include any of the surfactants, therapeutic agents, solubilizers and additives previously described. An additional amount of therapeutic agent is included in the composition.
• the composition contains two phases: a clear aqueous dispersion of the triglyceride and surfactants containing a first, solubilized amount of the therapeutic agent, and a second, non-solubilized amount of the therapeutic agent dispersed therein.
• a clear aqueous dispersion of the triglyceride and surfactants containing a first, solubilized amount of the therapeutic agent, and a second, non-solubilized amount of the therapeutic agent dispersed therein.
• the resultant multi-phase dispersion will not have the optical clarity of a dispersion in which the therapeutic agent is fully solubilized, but will appear to be cloudy, due to the presence of the non-solubilized phase.
• Such a formulation may be useful, for example, when the desired dosage of a therapeutic agent exceeds that which can be solubilized in the carrier and/or triglyceride.
• the formulation may also contain additives, as described above.
• a therapeutic agent may have a greater solubility in the pre-concentrate composition than in the aqueous dispersion, so that meta- stable, supersaturated solutions having apparent optical clarity but containing a therapeutic agent in an amount in excess of its solubility in the aqueous dispersion can be formed.
• Such super-saturated solutions whether characterized as clear aqueous dispersions (as initially formed) or as multi-phase solutions (as would be expected if the meta-stable state breaks down), are also within the scope ofthe present invention.
• the multi-phase formulation can be prepared by the methods described above.
• a pre-concentrate is prepared by simple mixing of the components, with the aid of gentle heating, if desired. It is convenient to consider the therapeutic agent as divided into two portions, a first solubilizable portion which will be solubilized and contained within the clear aqueous dispersion upon dilution, and a second non-solubilizable portion which will remain non-solubilized. When the ultimate dosage form is non-aqueous, the first and second portions of the therapeutic agent are both included in the pre-concentrate mixture.
• the composition can be prepared in the same manner, and upon dilution in an aqueous system, the composition will form the two phases as described above, with the second non-solubilizable portion of the therapeutic agent dispersed or suspended in the aqueous system, and the first solubilizable portion of the therapeutic agent solubilized in the composition.
• the pre-concentrate can be prepared including only the first, solubilizable portion of the therapeutic agent. This pre-concentrate can then be diluted in an aqueous system to form a clear aqueous dispersion, to which is then added the second, non- solubilizable portion ofthe therapeutic agent to form a multi-phase aqueous composition.
• the present invention relates to methods of increasing the solubilization of a therapeutic agent in a composition, by providing the therapeutic agent in a composition of the present invention.
• the composition can be any of the compositions described herein, with or without a therapeutic agent. It is surprisingly found that by using the combinations of triglycerides and surfactants described herein, greater amounts of triglycerides can be solubilized, without resort to unacceptably high concentrations of hydrophilic surfactants.
• the present invention relates to methods of increasing the rate and/or extent of absorption of therapeutic agents by administering to a patient a pharmaceutical composition of the present invention.
• the therapeutic agent can be present in the pharmaceutical composition pre-concentrate, in the diluent, or in a second pharmaceutical composition, such as a conventional commercial formulation, which is co-administered with a pharmaceutical composition ofthe present invention.
• a second pharmaceutical composition such as a conventional commercial formulation
• the delivery of therapeutic agents in conventional pharmaceutical compositions can be improved by co-administering a pharmaceutical composition of the present invention with a conventional composition.
• compositions of the present invention have the following characteristics:
• Rapid formation upon dilution with an aqueous solution, the composition forms a clear dispersion very rapidly; i.e., the clear dispersion appears to form instantaneously.
• the dispersions are essentially optically clear to the naked eye, and show no readily observable signs of heterogeneity, such as turbidity or cloudiness. More quantitatively, dispersions of the pharmaceutical compositions of the present invention have absorbances (400 nm) of less than about 0.3, and often less than about 0.1, at 100X dilution, as described more fully in the Examples herein. In the multi-phase embodiment ofthe compositions described herein, it should be appreciated that the optical clarity ofthe aqueous phase will be obscured by the dispersed particulate non-solubilized therapeutic agent.
• the dispersions are surprisingly stable to dilution in aqueous solution.
• the hydrophobic therapeutic agent remains solubilized for at least the period of time relevant for absorption.
• conventional triglyceride-containing formulations suffer the disadvantage that bioabsorption of the therapeutic agents contained therein is dependent upon enzymatic degradation (lipolysis) of the triglyceride components.
• the solubilization of the triglyceride in an aqueous medium is usually limited if only a hydrophilic surfactant is used to disperse the triglyceride, as is conventional.
• the triglyceride is present in the form of relatively large oil droplets.
• the large size of the triglyceride particles impedes the transport and absorption of the triglyceride or therapeutic agent solubilized in the triglyceride or in the carrier.
• the large, thermodynamically unstable triglyceride particles could further impose a risk when the compositions are administered intravenously, by plugging the blood capillaries.
• To achieve a high level of fully-solubilized triglyceride would require an amount of the hydrophilic surfactant exceeding that which would be bioacceptable.
• compositions of the present invention solve these and other problems of the prior art by adding a third component, a hydrophobic surfactant or a second hydrophilic surfactant.
• a third component a hydrophobic surfactant or a second hydrophilic surfactant.
• the solubilization ofthe triglyceride in the aqueous system is thereby unexpectedly enhanced. It is also unexpectedly found that the total amount of solubilized water-insoluble components, the triglyceride and hydrophobic surfactant, can greatly exceed the amount of the hydrophobic surfactant alone that can be solubilized using the same amount ofthe hydrophilic surfactant.
• compositions and methods of the present invention present a number of significant and unexpected advantages, including:
• the present compositions and methods allow for increased levels of triglyceride relative to hydrophilic surfactants, thereby reducing the need for excessively large amounts of hydrophilic surfactant. Further, the triglyceride-containing compositions of the present invention present small particle sizes, thus avoiding the problems of large particle size in conventional triglyceride-containing formulations and the concomitant safety concerns in parenteral administration.
• Efficient transport The particle sizes in the aqueous dispersions of the present invention are much smaller than the larger particles characteristic of vesicular, emulsion or microemulsion phases. This reduced particle size enables more efficient dmg transport through the intestinal aqueous boundary layer, and through the absorptive b sh border membrane. More efficient transport to absorptive sites leads to improved and more consistent absorption of therapeutic agents.
• Less-dependence on lipolysis The lack of large particle-size triglyceride components provides pharmaceutical compositions less dependent upon lipolysis, and upon the many poorly characterized factors which affect the rate and extent of lipolysis, for effective presentation of a therapeutic agent to an absorptive site.
• compositions which may inhibit lipolysis include the presence of composition components which may inhibit lipolysis; patient conditions which limit production of lipase, such as pancreatic lipase secretory diseases; and dependence of lipolysis on stomach pH, endogenous calcium concentration, and presence of co-lipase or other digestion enzymes.
• the reduced lipolysis dependence further provides transport which is less prone to suffer from any lag time between administration and absorption caused by the lipolysis process, enabling a more rapid onset of therapeutic action and better bioperformance characteristics.
• pharmaceutical compositions of the present invention can make use of hydrophilic surfactants which might otherwise be avoided or limited due to their potential lipolysis inhibiting effects.
• Non-dependence on bile and meal fat contents Due to the higher solubilization potential over bile salt micelles, the present compositions are less dependent on endogenous bile and bile related patient disease states, and meal fat contents. These advantages overcome meal-dependent absorption problems caused by poor patient compliance with meal-dosage restrictions.
• compositions of the present invention enable superior loading capacity over conventional formulations.
• particular combination of surfactants used can be optimized for a specific therapeutic agent to more closely match the polarity distribution of the therapeutic agent, resulting in still further enhanced solubilization.
• the therapeutic agents Due to the robustness of compositions of the present invention to dilution, the therapeutic agents remain solubilized and thus do not suffer problems of precipitation of the therapeutic agent in the time frame relevant for absorption.
• the therapeutic agent is presented in small particle carriers, and is not limited in dilution rate by entrapment in emulsion carriers. These factors avoid liabilities associated with the poor partitioning of lipid solubilized dmg in to the aqueous phase, such as large emulsion droplet surface area, and high interfacial transfer resistance, and enable rapid completion ofthe critical partitioning step.
• Aqueous dispersions of the present invention are thermodynamically stable for the time period relevant for absorption, and can be more predictably reproduced, thereby limiting variability in bioavailability— a particularly important advantage for therapeutic agents with a narrow therapeutic index.
• Efficient release The compositions of the present invention are designed with components that help to keep the therapeutic agent or absorption promoter, such as a permeation enhancer, an enzyme inhibitor, etc., solubilized for transport to the absorption site, but readily available for absorption, thus providing a more efficient transport and release.
• Less prone to gastric emptying delays Unlike conventional triglyceride- containing formulations, the present compositions are less prone to gastric emptying delays, resulting in faster absorption. Further, the particles in dispersions of the present invention are less prone to unwanted retention in the gastro-intestinal tract.
• the pharmaceutical compositions of the present invention allow for faster transport of the therapeutic agent through the aqueous boundary layer.
• a simple pre-concentrate is prepared as follows. Predetermined weighed amounts of the surfactants and triglyceride are stirred together to form a homogeneous mixture. For combinations that are poorly miscible, the mixture can be gently heated to aid in formation of the homogeneous mixture. If the composition is to include a therapeutic agent, the chosen therapeutic agent in a predetermined amount is added and stirred until solubilized. Optionally, solubilizers or additives are included by simple mixing.
• a predetermined amount of purified water, buffer solution, or aqueous simulated physiological solution is added to the pre-concentrate, and the resultant mixture is stirred to form a clear, aqueous dispersion.
• Example 2 Triglyceride Solubilization in Conventional Formulations
• compositions of the present invention Conventional formulations of a triglyceride and a hydrophilic surfactant were prepared for comparison to compositions of the present invention. For each surfactant- triglyceride pair, multiple dispersions were prepared with differing amounts of the two components, to determine the maximum amount of the triglyceride that can be present while the composition still forms a clear dispersion upon a 100-fold dilution with distilled water. No therapeutic agent was included in these compositions, since it is believed that the presence ofthe therapeutic agent does not substantially affect the clear, aqueous nature of composition. For the same reason, these compositions were free of additional solubilizers and other additives. The optical clarity was determined by visual inspection and/or by UV absorption (at 400 nm). When UV absorption was used, compositions were considered to be clear when the absorption was less than about 0.2.
• Table 20 shows the maximum amount of triglyceride present in such binary mixtures forming clear aqueous dispersions.
• the numerical entries in the Table are in units of grams of triglyceride per 100 grams of hydrophilic surfactant.
• Example 2 The procedure of Example 2 was repeated for compositions containing PEG-40 hydrogenated castor oil (Cremophor RH 40) or polysorbate 80 (Tween 80) as the hydrophilic surfactant, but substituting a second hydrophilic surfactant (compositions number 6-7 and 14-16) or a hydrophobic surfactant (compositions number 4-5, 8-9, and ⁇ ⁇ 17-18) for part of the hydrophilic surfactant. The total amount of hydrophilic surfactant was kept constant. The results are summarized in Table 21.
• Tween 80 100 100 100 100 100 67 67 67 67 67 67 67 67 67
• the clear or hazy appearance noted in the Table is that of the pre-concentrate, not of the aqueous dispersion.
• the clarity of the aqueous dispersion is shown quantitatively by UV absorption ofthe 100X dilution at 400 nm.
• compositions 1-3 a binary com oil-Cremophor RH-40 mixture having
• compositions 4-5 show the surprising result that when part of the hydrophilic Cremophor RH-40 is replaced by a hydrophobic surfactant 0 (Peceol), keeping the total surfactant concentration constant, compositions having a much higher amount of triglyceride (40 grams) still form clear aqueous dispersions, with absorbances less than 0.2 and dramatically less than the comparable binary composition number 3.
• a similar result is shown in compositions 8-9 for a different hydrophobic surfactant, Crovol M-40.
• part of the hydrophilic surfactant is replaced by a hydrophobic surfactant 0 (Peceol)
• compositions 6-7 25 a second hydrophilic surfactant in compositions 6-7, it is surprisingly found that the amount of triglyceride solubilized is similarly increased.
• Table 2 IB shows a similar surprising result for a different hydrophilic surfactant, Tween 80.
• Simple binary com oil-Tween 80 mixtures form clear aqueous dispersions with 10 grams of com oil, but are cloudy and multi -phasic
• Example 3 Effect of Surfactant Combinations Example 3 was repeated, using different triglyceride-surfactant combinations. In particular, medium-chain triglycerides (MCTs) were used instead of com oil, a long-chain triglyceride (LCT). The results are shown in the three-part Table 22.
• MCTs medium-chain triglycerides
• LCT long-chain triglyceride
• Table 22 shows that the increased solubilization of the triglyceride is observed for MCTs as well as for LCTs, with a variety of surfactants. Table 22 additionally shows that the same effect is observed in the presence of increased amounts of surfactants (compositions 23 and 27) and solubilizers (composition 23).
• Example 5 Characterization of Compositions Various compositions were prepared and characterized by visual observation as well as by UV absorbance at 400 nm. Each composition was diluted 100-fold with distilled water. The results are shown in Table 23. Table 23: Visual and Spectroscopic Characterization
• compositions of the present invention Prior art formulations were prepared for comparison with the compositions of the present invention. As in Example 5, the compositions were diluted 100-fold with distilled water, and characterized by visual observation and by UV absorbance. The results are shown in Table 24.
• Patent No. 5,645,856 form milky suspensions rather than the clear aqueous dispersions of the present invention.
• Example 7 Formulations with Therapeutic Agents Table 25 shows several formulations of compositions that can be prepared according to the present invention, using a variety of therapeutic agents.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Biophysics (AREA)
• Molecular Biology (AREA)
• Dispersion Chemistry (AREA)
• Medicinal Preparation (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=23355749

Family Applications (1)

Country Status (7)

Cited By (81)

Families Citing this family (346)

Citations (2)

Family Cites Families (51)

• 1999
  • 1999-06-30 US US09/345,615 patent/US6267985B1/en not_active Expired - Lifetime
• 2000
  • 2000-06-02 CA CA2375083A patent/CA2375083C/en not_active Expired - Lifetime
  • 2000-06-02 WO PCT/US2000/015133 patent/WO2001001960A1/en not_active Ceased
  • 2000-06-02 JP JP2001507455A patent/JP2003503440A/ja active Pending
  • 2000-06-02 NZ NZ516521A patent/NZ516521A/en not_active IP Right Cessation
  • 2000-06-02 EP EP00938039A patent/EP1194120A4/en not_active Withdrawn
  • 2000-06-02 AU AU53131/00A patent/AU783077B2/en not_active Ceased
  • 2000-06-02 EP EP08016180A patent/EP2000130A1/en not_active Withdrawn
• 2011
  • 2011-06-07 JP JP2011126945A patent/JP2011201914A/ja active Pending

Patent Citations (2)

Non-Patent Citations (1)